Table 1.
Cohort Demographics and Baseline Characteristics
| Phenytoin | Lamotrigine | ||
|---|---|---|---|
| N=93 | Study Cohort N=45 |
Rivas, et al. cohort N=600 |
|
| Male, % | 51 | 51 | 56 |
| Age, years* | 61 (49, 71) | 43 (31, 50) | 38-39 (26.8, 51.3)** |
| Body weight, kg* | 78 (67, 91) | 78.5 (65.8, 99.3) | 70.0-76.0 (61.8, 85.0)** |
| White race, % | 53 | 64 | NR |
| Hematocrit* | 0.32 (0.27, 0.36) | 0.36 (0.28, 0.41) | NR |
| White blood cell count, ×103/ml* | 9.80 (7.75, 12.85) | 8.90 (5.70, 11.45) | NR |
| Platelet count, ×103/ml* | 208.5 (138.0, 276.5) | 217.0 (140.5, 269.0) | NR |
| Concomitant medication usage, % | |||
| Carbamazepine | 1.1 | 2.2 | 15 |
| Valproate | 0 | 8.9 | 29 |
| Phenobarbital | 7.5 | 0 | 5.1 |
| Diazepam | 6.5 | 0 | NR |
| Clonazepam | 14 | 0 | NR |
| Fluconazole | 5.4 | 0 | NR |
| Phenytoin | NA | 6.7 | NR |
NA, not applicable; NR, not reported
*
Data presented as median (25th, 75th percentile)
**
Combined data from 2 cohorts were used in the study. Data presented as cohort 1 median – cohort 2 median, (25th, 75th percentile)